Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06453850

Safety and Performance Evaluation of a New Catheter Range for Lead Implantation At Interventricular Septum

Led by MicroPort CRM · Updated on 2025-03-06

216

Participants Needed

3

Research Sites

93 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the clinical investigation is to evaluate the safety of the FLEXIGO delivery catheter for transvenous pacing lead implantation.

CONDITIONS

Official Title

Safety and Performance Evaluation of a New Catheter Range for Lead Implantation At Interventricular Septum

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
  • Patient planned for a de novo implantation of any Single Chamber (SR) or Dual Chamber (DR) CE marked pacemaker
  • Patient planned for a catheter-guided implantation in the interventricular septum area
  • Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter
  • Patient reviewed, signed and dated the Informed Consent Form (ICF)
  • Patient indicated for cardiac pacing or CRT according to the most recent guidelines from the ESC
  • Patient planned for a de novo implantation of any SR or DR CE marked pacemaker, or any CE marked CRT-D
  • Patient planned for a catheter-guided implantation in the interventricular septum area
  • Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter
  • Patient reviewed, signed and dated the ICF
Not Eligible

You will not qualify if you...

  • Patient planned for a device upgrade, or a device or a lead replacement
  • Patient with a congenital heart disease
  • Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy
  • Patient with a Left Ventricular Ejection Fraction (LVEF) C= 35%
  • Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
  • Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 bcg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
  • Minor age patient (i.e. under 18 years of age)
  • Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
  • Non-menopausal women
  • Patient planned for a device upgrade, or a device or a lead replacement
  • Patient with a congenital heart disease
  • Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy
  • Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
  • Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 bcg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
  • Minor age patient (i.e. under 18 years of age)
  • Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
  • Non-menopausal women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

ULS de Coimbra

Coimbra, Portugal

Actively Recruiting

2

Hospital Universitario Virgen de las Nieves

Granada, Spain

Actively Recruiting

3

Hospital Universitari i Politècnic La Fe

Valencia, Spain

Actively Recruiting

Loading map...

Research Team

A

Antoine Guihard

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here